Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H1 2017, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.
B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms or in the groin, pain or discomfort under the ribs on the left side, due to an enlarged spleen, frequent or repeated infections and slow healing, due to a lack of normal white blood cells, excessive sweating at night and unintentional weight loss. Treatment includes chemotherapy and radiation.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 7, 12 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 2 molecules, respectively.
B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AB Science SA
Aduro BioTech Inc
BioInvent International AB
Boehringer Ingelheim GmbH
Celgene Corp
Cell Source Inc
Cellectis SA
Dynavax Technologies Corp
Eisai Co Ltd
Elsalys Biotech SAS
F. Hoffmann-La Roche Ltd
iDD biotech SAS
Immunomedics Inc
Johnson & Johnson
Juno Therapeutics Inc
Lymphocyte Activation Technologies SA
Mabion SA
MedImmune LLC
MEI Pharma Inc
Millennium Pharmaceuticals Inc
Molecular Templates Inc
Noxxon Pharma AG
Ono Pharmaceutical Co Ltd
Regeneron Pharmaceuticals Inc
Sunesis Pharmaceuticals Inc
Unum Therapeutics Inc
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
B-Cell Chronic Lymphocytic Leukemia – Overview
B-Cell Chronic Lymphocytic Leukemia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
B-Cell Chronic Lymphocytic Leukemia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
B-Cell Chronic Lymphocytic Leukemia – Companies Involved in Therapeutics Development
AB Science SA
Aduro BioTech Inc
BioInvent International AB
Boehringer Ingelheim GmbH
Celgene Corp
Cell Source Inc
Cellectis SA
Dynavax Technologies Corp
Eisai Co Ltd
Elsalys Biotech SAS
F. Hoffmann-La Roche Ltd
iDD biotech SAS
Immunomedics Inc
Johnson & Johnson
Juno Therapeutics Inc
Lymphocyte Activation Technologies SA
Mabion SA
MedImmune LLC
MEI Pharma Inc
Millennium Pharmaceuticals Inc
Molecular Templates Inc
Noxxon Pharma AG
Ono Pharmaceutical Co Ltd
Regeneron Pharmaceuticals Inc
Sunesis Pharmaceuticals Inc
Unum Therapeutics Inc
B-Cell Chronic Lymphocytic Leukemia – Drug Profiles
202-b – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-8779 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alemtuzumab biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alisertib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-1206 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-836826 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BION-1301 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Chronic Lymphocytic Leukemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Hematological Malignancies – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD19 for B-Cell Malignancies – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD19 for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD19 for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD19 for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DTRMWXHS-12 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-7449 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELB-021 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDD-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDD-002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-64052781 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenalidomide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ME-401 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mRNA ACTR + rituximab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-3724 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olaptesed pegol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-1979 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SD-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNS-062 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAB-08 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tirabrutinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UCART-22 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UCARTCS-1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-Cell Chronic Lymphocytic Leukemia – Dormant Projects
B-Cell Chronic Lymphocytic Leukemia – Discontinued Products
B-Cell Chronic Lymphocytic Leukemia – Product Development Milestones
Featured News & Press Releases
Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on SNS-062
Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement
Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by AB Science SA, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Aduro BioTech Inc, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by BioInvent International AB, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Boehringer Ingelheim GmbH, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Celgene Corp, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Cell Source Inc, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Cellectis SA, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Dynavax Technologies Corp, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Eisai Co Ltd, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Elsalys Biotech SAS, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by iDD biotech SAS, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Immunomedics Inc, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Johnson & Johnson, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Juno Therapeutics Inc, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Lymphocyte Activation Technologies SA, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Mabion SA, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by MedImmune LLC, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by MEI Pharma Inc, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Millennium Pharmaceuticals Inc, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Molecular Templates Inc, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Noxxon Pharma AG, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Sunesis Pharmaceuticals Inc, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Pipeline by Unum Therapeutics Inc, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Dormant Projects, H1 2017
B-Cell Chronic Lymphocytic Leukemia – Dormant Projects, H1 2017 (Contd..1), H1 2017
B-Cell Chronic Lymphocytic Leukemia – Discontinued Products, H1 2017
List of Figures
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
